ClinicalTrials.gg
RecruitingNCT06071013Updated Jan 23, 2025

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

A Phase 1/2 interventional study of Nintedanib, gefitinib, erlotinib, afatinib, osimertinib in Non-small Cell Lung Cancer, EGFR Gene Mutation and EGFR-TKI Resistant Mutation, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by China Medical University Hospital · Phase 1/2, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
7th of 19
20 · median 16
Started
2024
the only one that year
Phase 1/2
3 of 19
1 open now
Registered
19th of 19
by date
Lead sponsor
1 of 19
China Medical University Hospital

Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 3 in phase 1/2, and was the 19th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country.

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer

Read the detailed description

The efficacy of the regimen is evaluated by participants' progression-free survival and overall survival.

Nintedanib is a medication that blocks endothelial cells in tumor microenvironments and is effective in delaying tumor progression. Nintedanib is also a drug approved for idiopathic pulmonary fibrosis in the clinic.

The participants will take 1 nintedanib tablet after a meal twice per day with a twelve-hour interval. EGFR TKI-gefitinib, erlotinib, afatinib, or osimertinib will be taken 1 tablet once per day during each treatment cycle. The treatment cycle in this study is 30 days.

In this study, the participants will have a physical exam in 6 weeks and 12 weeks after the initiation of the treatment. In the 6 weeks of the study, the participants will have blood tests and a CT scan. About 5cc of blood will be collected each time. In addition, the participant's tumor will be measured by a CT scan every 12 weeks.

If the participants develop any unacceptable symptoms or changes in liver function tests, the participants' treatment may be delayed and/or the dose decreased until the symptoms are disappeared. It may even be necessary to stop your treatment. The doctor will inform the participant of any changes in the participants' treatment schedule or in the doses of medication after he/she evaluates the participants in the clinic.

After treatment ends, the participants will have a follow-up visit at the clinic. At this visit, the participants will have a complete physical exam, including blood (about 5cc) tests and CT scan to measure the size of the tumors.

This is an investigational study. Up to 20 participants will take part in this study.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • EGFR Gene Mutation
  • EGFR-TKI Resistant Mutation

Keywords

  • nPKC delta
  • Angiogenesis
  • EGFR TKI drug resistant
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants between 20 to 70 years old, are confirmed advanced (stage III and IV) non-small cell lung cancer.
  2. Positive EGFR mutations are diagenesis.
  3. Participants with histologically/cytologically confirmed locally advanced or adenocarcinoma subtype NSCLC after the failure of EGFR tyrosine kinase inhibitors- gefitinib, erlotinib, afatinib, or osimertinib.
  4. Participants must have adequate hepatic, renal, and bone marrow function

Exclusion criteria

Exclusion Criteria:

  1. Participants previously received EGFR tyrosine kinase inhibitor with serious side effects.
  2. Participants have known hypertension, and chronic liver and gastrointestinal disease.
  3. Participants have known .
  4. Female participants who are pregnant or breast-feeding
  5. Participants have a known diagnosis of negative nPKCδ expression by immunohistochemistry (IHC).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Nintedanib + gefitinib/erlotinib/afatinib/osimertinib

    Nintedanib will administered orally twice per day Gefitinib will administered orally once daily Erlotinib will administered orally once daily Afatinib will administered orally once daily Osimertinib will administered orally once daily

    Drug: Nintedanib, gefitinib, erlotinib, afatinib, osimertinib

Interventions

  • DrugNintedanib, gefitinib, erlotinib, afatinib, osimertinib

    Drug pages: NintedanibStudies of NintedanibNintedanib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GefitinibStudies of GefitinibGefitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ErlotinibStudies of ErlotinibErlotinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AfatinibStudies of AfatinibAfatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · OsimertinibStudies of OsimertinibOsimertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration. Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells.

06

What researchers measure

Primary outcomes

  1. The toxicity of combinate nintedanib and EGFR TKI

    Time frame: Assessed every 6 weeks of chest CT scan until PD.

  2. Patient objective response rate

    Time frame: Assessed every 6 weeks of chest CT scan

Secondary outcomes

  1. Overall survival

    Time frame: Assessed every 12 weeks thereafter up to end of study at approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Aug 2026, 30 months after the start.

Of 124 non-industry phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 107. This study's planned 30 months is below that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 6, 2023
StartActual
Feb 23, 2024
Primary completionEst.
Aug 27, 2026
CompletionEst.
Aug 27, 2026
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06071013
Collaborators
China Medical University, Taiwan
Responsible party
Sponsor
First posted
Oct 6, 2023
Start date
Feb 23, 2024
Primary completion
Aug 27, 2026 (estimated)
Completion
Aug 27, 2026 (estimated)
Last update
Jan 23, 2025

Study contacts

Chih-Yen Tu
Contact
chesttu@gmail.com
+886-975-681-007
Pulmonary Medicine
study director · China Medical University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Gefitinib · Erlotinib · Afatinib · Osimertinib

Start the discussion